泪囊炎市场- 治疗（手术、药物{抗生素}）、适应症（慢性泪囊炎、急性泪囊炎、先天性泪囊炎）、最终用户（机构销售、零售） - 全球预测（2024 - 2032 ）

由于人们对泪囊炎的认识和诊断不断提高，以及易患眼部感染的老年人口不断增加，全球泪囊炎市场在 2024 年至 2032 年间的复合年增长率将超过 5.3%。复杂的诊断工具和微创手术技术等创新彻底改变了治疗方法，带来更准确的诊断和有效的治疗。这些技术进步缩短了患者的復原时间并改善了治疗结果。举个例子，2023 年 5 月，博士伦和 Novaliq 宣布 FDA 批准 MIEBO(TM)（全氟己基辛烷眼用溶液）用于治疗干眼症。 MIEBO 是第一个获得 FDA 批准的针对泪液蒸发的眼药水，基于关键 3 期试验的成功结果。

高解析度内视镜等增强成像技术可以更好地可视化泪囊和导管系统，有助于对泪囊炎进行精确干预。此外，先进治疗程序的开发有助于提高效率和病人安全，从而促进市场成长。

整个泪囊炎市场根据治疗、适应症、最终用户和地区进行细分。

由于认知和诊断率不断提高，到 2032 年，药物领域将呈现强劲的复合年增长率。医疗保健服务的改善导致更多患者寻求治疗，从而刺激了对有效药物选择的需求。医学研究的进步导致新药物配方和疗法的开发。慢性病的盛行率不断上升和人口老化导致泪囊炎的盛行率更高。随着患者和医疗保健提供者寻求治疗泪囊炎的创新解决方案，对药物的需求将会增加。

由于急诊症状的发生率较高，到 2032 年，急性泪囊炎细分市场将占据重要的市场份额。急性泪囊炎的特征是泪囊突然发炎感染，需要立即就医。细菌感染激增和环境触发因素等因素导致病例增加。此外，诊断能力的提高使得更多病例得以及早发现。患者意识的提高和积极主动的医疗保健实践推动了对有效管理解决方案的需求，以确保快速缓解急性症状并减少潜在的併发症。

由于人们对该疾病的认识不断提高和早期诊断，欧洲泪囊炎市场从 2024 年到 2032 年将呈现强劲的复合年增长率。公共卫生措施和教育活动正在导致更多的人寻求及时治疗。欧洲先进的医疗保健基础设施促进了专业护理的取得，扩大了需求。该地区人口老化，更容易受到眼部感染，这增加了对有效泪囊炎管理解决方案的需求。这些因素共同促成了正面的市场前景。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 慢性和先天性泪囊炎的盛行率不断增加
    • 对先进眼科治疗方案的认识不断增强
    • 人口老化加剧
    • 先进的诊断技术可及时诊断泪囊炎
  • 产业陷阱与挑战
    • 存在严格的法规
    • 副作用风险高
• 成长潜力分析
• 监管环境
• 未来市场趋势
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司市占率分析
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按处理方式，2021 - 2032

• 主要趋势
• 手术
• 药物
  • 抗生素
  • 其他药物

第 6 章：市场估计与预测：按指标划分，2021 - 2032 年

• 主要趋势
• 慢性泪囊炎
• 急性泪囊炎
• 先天性泪囊炎

第 7 章：市场估计与预测：按配销通路，2021 - 2032

• 主要趋势
• 机构销售
• 零售额

第 8 章：市场估计与预测：按地区，2021 - 2032

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋
  • 中东和非洲其他地区

第 9 章：公司简介

• AbbVie Inc. (Allergan)
• Alcon Inc.
• Aurolab
• Bausch Health Companies Inc.
• Bayer AG
• BVM Medical Limited
• F. Hoffmann-La Roche Ltd (Genentech, Inc.)
• FCI Ophthalmics
• Gunther Weiss Scientific Glassblowing Co., Inc.
• Heart Medical Europe BV
• Kaneka Corporation
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Regeneron Pharmaceuticals Inc.

Global Dacryocystitis Market will record over 5.3% CAGR between 2024 and 2032, catapulted by increasing awareness & diagnosis of the condition, and a rising geriatric population susceptible to eye infections. Innovations such as sophisticated diagnostic tools and minimally invasive surgical techniques have revolutionized treatment approaches, leading to more accurate diagnoses and effective therapies. These technological advancements cut patient recovery time and improve treatment outcomes. Quoting an instance, in May 2023, Bausch + Lomb and Novaliq announced FDA approval of MIEBO(TM) (perfluorohexyloctane ophthalmic solution) for treating dry eye disease. MIEBO is the first FDA-approved eye drop targeting tear evaporation, based on successful results from pivotal Phase 3 trials.

Enhanced imaging technologies, such as high-resolution endoscopy, allow for better visualization of the lacrimal sac and duct systems, facilitating precise interventions for dacryocystitis. Additionally, the development of advanced therapeutic procedures contributes to augmenting efficiency and patient safety, ushering the market growth.

The overall dacryocystitis market is segmented based on treatment, indication, end user, and region.

The medication segment will exhibit a robust CAGR through 2032, because of increasing awareness and diagnosis rates. Improved healthcare access is leading to more patients seeking treatment, spurring the need for effective medication options. Advancements in medical research are resulting in the development of new drug formulations and therapies. The growing prevalence of chronic conditions and an aging population lead to higher prevalence of dacryocystitis. As patients and healthcare providers seek innovative solutions for managing dacryocystitis, the demand for medications will increase.

The acute dacryocystitis segment will achieve a significant market share by 2032, owing to the higher incidence of rapid-onset symptoms. Acute dacryocystitis, characterized by sudden inflammation and infection of the lacrimal sac, requires prompt medical attention. Factors such as an upsurge in bacterial infections and environmental triggers leads to increased cases. Additionally, improved diagnostic capabilities have led to more cases being identified early. Increased patient awareness and proactive healthcare practices drive demand for effective management solutions, ensuring rapid relief from acute symptoms and reducing potential complications.

Europe dacryocystitis market will show a strong CAGR from 2024 to 2032, due to rising awareness and early diagnosis of the condition. The public health initiatives and educational campaigns are leading to more individuals seeking timely treatment. Europe's advanced healthcare infrastructure facilitates access to specialized care, amplifying demand. The region's aging population, which is more susceptible to eye infections, is boosting the need for effective dacryocystitis management solutions. These factors collectively contribute to a positive market outlook.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of chronic and congenital dacryocystitis
    • 3.2.1.2 Growing awareness towards advanced ophthalmic treatment options
    • 3.2.1.3 Increasing aging population
    • 3.2.1.4 Availability of advanced diagnostic techniques to timely diagnose dacryocystitis
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Presence of stringent regulations
    • 3.2.2.2 High risk of side effects
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Future market trends
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Treatment, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Surgery
• 5.3 Medication
  • 5.3.1 Antibiotics
  • 5.3.2 Other medications

Chapter 6 Market Estimates and Forecast, By Indication, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Chronic dacryocystitis
• 6.3 Acute dacryocystitis
• 6.4 Congenital dacryocystitis

Chapter 7 Market Estimates and Forecast, By Distribution channel, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Institutional sales
• 7.3 Retail sales

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 AbbVie Inc. (Allergan)
• 9.2 Alcon Inc.
• 9.3 Aurolab
• 9.4 Bausch Health Companies Inc.
• 9.5 Bayer AG
• 9.6 BVM Medical Limited
• 9.7 F. Hoffmann-La Roche Ltd (Genentech, Inc.)
• 9.8 FCI Ophthalmics
• 9.9 Gunther Weiss Scientific Glassblowing Co., Inc.
• 9.10 Heart Medical Europe BV
• 9.11 Kaneka Corporation
• 9.12 Merck & Co., Inc.
• 9.13 Novartis AG
• 9.14 Pfizer Inc.
• 9.15 Regeneron Pharmaceuticals Inc.